Shares of Sagimet Biosciences soared nearly 40% on Monday, reaching levels not seen since March 2024, as retail sentiment surged following news of an upcoming presentation linked to its lead drug ...

Using fermentation, University of Alberta researchers have come up with a way to produce higher amounts of a healthy fatty ...

Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report). The ...

Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

and fatty acids is coupled to the generation of an electrochemical gradient across the inner mitochondrial membrane, which is harnessed by the ATP synthase to drive the formation of ATP.

Expert Rev Cardiovasc Ther. 2008;6(3):391-409. Phosphatidic acid phosphatase/phosphohydrolase (PAP) is an enzyme that catalyzes the conversion of phosphatidic acid to ...